SCHEMBL1536088

SCHEMBL1536088

CCOC(=O)NC1CC(C(=O)O)C2CC12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
LMNA P02545 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.34
CPB1 P15086 1/20 0.33
ATM Q13315 1/20 0.33
HSD11B1 P28845 1/20 0.33
GAA P10253 3/20 0.33
EPHX2 P34913 1/20 0.32
IDO1 P14902 1/20 0.32
CYP2C19 P33261 2/20 0.31
MGAM O43451 1/20 0.31
SI P14410 1/20 0.31
MGAM2 Q2M2H8 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
GLA P06280 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4354337 0.86 CPB1 (0.40) NFKB1NFKB2RELALMNATRPM8
SCHEMBL4354339 0.86 CPB1 (0.40) NFKB1NFKB2RELALMNATRPM8
SCHEMBL23615849 0.77 NFKB1 (0.40) NFKB1NFKB2RELACPB1ALDH1A1
SCHEMBL9427030 0.74 NFKB1 (0.38) NFKB1NFKB2RELALMNATRPM8
SCHEMBL9567786 0.74 NFKB1 (0.38) NFKB1NFKB2RELALMNATRPM8
SCHEMBL27916805 0.72 NFKB1 (0.44) NFKB1NFKB2RELALMNATRPM8
SCHEMBL19052833 0.71 F2R (0.44) NFKB1NFKB2RELALMNATRPM8
SCHEMBL4814717 0.70 NFKB1 (0.45) NFKB1NFKB2RELALMNAATM
SCHEMBL4814731 0.70 NFKB1 (0.45) NFKB1NFKB2RELALMNAATM
SCHEMBL4814709 0.70 NFKB1 (0.45) NFKB1NFKB2RELALMNAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2018-10-11 US disclosed
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-11-10 US disclosed
EP-3031324-A2 TRICYCLIC KINASE INHIBITORS AbbVie Inc. (US) 2016-06-15 EP disclosed
US-9365579-B2 Tricyclic compounds ABBVIE INC. (US) 2016-06-14 US disclosed
EP-2299821-B1 TRICYCLIC COMPOUNDS ABBVIE INC (US) 2015-11-04 EP disclosed
US-20150210708-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2015-07-30 US disclosed
US-8962629-B2 Tricyclic compounds ABBVIE INC. (US) 2015-02-24 US disclosed
EP-2299821-A1 NOVEL TRICYCLIC COMPOUNDS Abbott Laboratories (US) 2011-03-30 EP disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 US disclosed
WO-2009152133-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 NFKB1 807/4885NFKB2 1142/4885RELA 1178/4885
US-20090312338-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 NFKB1 807/4885NFKB2 1142/4885RELA 1178/4885
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 NFKB1 807/4885NFKB2 1142/4885RELA 1178/4885
US-20150210708-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 NFKB1 807/4885NFKB2 1142/4885RELA 1178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.